The Action Mechanism of Dendrobium spp. in Treating Dry Eye Disease Based on Network Pharmacology and In Vitro Experiments

Read full text Summarise with VIRAT
Authors: Shanshan Zhu, Jiayi Li, Yao Lu, C Sun, Yushan Zou, Yujie Wang, Siqi Wu, Jin Yao, Wen Bai
Cited by: 0
References: 50

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Dendrobium spp. has traditionally been used to improve visual function, and related formulations, such as Dendrobium Glow in dark pills, are currently used in the management of dry eye disease (DED). This study investigated the positive effects and underlying mechanisms of 3-O-methylgigantol, an active compound from Dendrobium spp., against DED using network pharmacology and in vitro experimental validation. Methods: Active compounds and targets were identified through database screening, and network analysis was used to identify the key compounds and targets. Molecular docking and dynamic simulations were performed to verify the binding of 3-O-methylgigantol to the epidermal growth factor receptor (EGFR). An in vitro DED model was established using hyperosmotic sodium chloride (550 mOsm) in human corneal epithelial cells (HCECs). The effects of 3-O-methylgigantol, with or without the EGFR inhibitor (erlotinib), on cell viability, apoptosis, reactive oxygen species, and inflammatory cytokines were assessed. Results: Network pharmacology predicted 3-O-methylgigantol as a key active compound and EGFR as a core target. Molecular simulations confirmed stable binding. In vitro experiments showed that 3-O-methylgigantol significantly increased HCEC viability and reduced apoptosis, reactive oxygen species accumulation, and inflammatory cytokine release under hyperosmotic conditions. The EGFR inhibitor erlotinib attenuated these protective effects. Conclusions: 3-O-methylgigantol, an active compound from Dendrobium spp., alleviates hyperosmolarity-induced corneal epithelial cell damage, oxidative stress, and inflammation by activating the EGFR signaling pathway. This compound may represent a potential therapeutic candidate for DED management, demonstrating its efficacy in restoring tear film homeostasis in in vitro models.

Fields of Study & Subjects

Ocular Surface and Contact Lens Biological and pharmacological studies of plants Salivary Gland Disorders and Functions

Publication details

Journal / source
Frontiers in Bioscience-Landmark
Volume
31
Issue
3
Pages
47218–47218
Publication date
18 March 2026
Language
EN